{"id":"serostim","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Arthralgia (joint pain)"},{"rate":"5-10","effect":"Myalgia (muscle pain)"},{"rate":"5-10","effect":"Carpal tunnel syndrome"},{"rate":"5-10","effect":"Edema (fluid retention)"},{"rate":"5","effect":"Hyperglycemia"},{"rate":"5-10","effect":"Injection site reactions"}]},"_chembl":{"chemblId":"CHEMBL1201621","moleculeType":"Protein"},"_dailymed":{"setId":"62b01d29-90f0-45b2-a0c4-3a750ba36c8a","title":"SEROSTIM (SOMATROPIN) KIT [EMD SERONO, INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Serostim (somatropin) is a synthetic form of human growth hormone that binds to growth hormone receptors, promoting protein synthesis, lipolysis, and increased lean body mass while reducing fat mass. In HIV-infected patients with wasting syndrome, it helps reverse the catabolic state and restore body composition. The drug enhances nitrogen retention and metabolic rate, counteracting the muscle-wasting effects of advanced HIV disease.","oneSentence":"Serostim is a recombinant human growth hormone that stimulates anabolic processes and increases lean body mass in patients with HIV-associated wasting.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:52:57.722Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-associated wasting or cachexia in patients with HIV infection and low body weight"}]},"trialDetails":[{"nctId":"NCT05330325","phase":"PHASE3","title":"A Research Study to Compare Somapacitan Once a Week With Norditropin® Once a Day in Children Who Need Help to Grow","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2022-08-10","conditions":"SGA, Turner Syndrome, Noonan Syndrome, ISS","enrollment":412},{"nctId":"NCT07221851","phase":"PHASE3","title":"Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders","status":"RECRUITING","sponsor":"Ascendis Pharma A/S","startDate":"2025-12-12","conditions":"Turner Syndrome, Short Stature Homeobox Gene Mutation, Idiopathic Short Stature","enrollment":186},{"nctId":"NCT07450001","phase":"PHASE1, PHASE2","title":"A Study of GenSci134 in Children With Growth Hormone Deficiency (PGHD)","status":"NOT_YET_RECRUITING","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","startDate":"2026-03-06","conditions":"Pediatric Growth Hormone Deficiency","enrollment":128},{"nctId":"NCT07450053","phase":"PHASE1, PHASE2","title":"A Study (Phase 1b/2) of GenSci134 in Children With Idiopathic Short Stature (ISS)","status":"NOT_YET_RECRUITING","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","startDate":"2026-03-06","conditions":"Idiopathic Short Stature","enrollment":128},{"nctId":"NCT07260500","phase":"PHASE2","title":"A Phase II Study of PEG-rhGH Injection for Short Children Born Small for Gestational Age: Efficacy, Safety, and Pharmacokinetics","status":"RECRUITING","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","startDate":"2025-11-11","conditions":"Short Stature Children Born Small for Gestational Age (SGA)","enrollment":72},{"nctId":"NCT05718570","phase":"","title":"A Study to Follow Patients With Adult Growth Hormone Deficiency (AGHD) Treated With Sogroya® for Long Term Safety Information","status":"ENROLLING_BY_INVITATION","sponsor":"Novo Nordisk A/S","startDate":"2023-02-03","conditions":"Adult Growth Hormone Deficiency","enrollment":400},{"nctId":"NCT05509894","phase":"","title":"Korean Post-marketing Surveillance Ngenla® Pre-filled Pen Injection for the Treatment of Pediatric Patients With Growth Disturbance Due to Insufficient Secretion of Growth Hormone","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2024-06-20","conditions":"Pediatric Growth Hormone Deficiency","enrollment":565},{"nctId":"NCT07359625","phase":"NA","title":"Effects of Ketone Bodies on Insulin Sensitivity","status":"RECRUITING","sponsor":"University of Aarhus","startDate":"2025-12-02","conditions":"Insulin Resistance, Obesity & Overweight, Energy Metabolism","enrollment":10},{"nctId":"NCT02616562","phase":"PHASE2","title":"Investigating Efficacy and Safety of Once-weekly NNC0195-0092 Treatment Compared to Daily Growth Hormone Treatment (Norditropin® FlexPro®) in Growth Hormone Treatment naïve Pre-pubertal Children With Growth Hormone Deficiency","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2016-03-31","conditions":"Growth Hormone Disorder, Growth Hormone Deficiency in Children","enrollment":76},{"nctId":"NCT04970654","phase":"PHASE3","title":"A Research Study in Chinese Children With a Low Level of Hormone to Grow. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day.","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-07-22","conditions":"Growth Hormone Deficiency in Children","enrollment":110},{"nctId":"NCT03811535","phase":"PHASE3","title":"A Research Study in Children With a Low Level of Hormone to Grow. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day (REAL4)","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2019-05-20","conditions":"Growth Hormone Deficiency in Children","enrollment":200},{"nctId":"NCT03878446","phase":"PHASE2","title":"A Research Study in Children Born Small and Who Stayed Small. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2019-07-04","conditions":"Short Stature Children Born Small for Gestational Age (SGA)","enrollment":62},{"nctId":"NCT06830525","phase":"","title":"Development of a Personalized Growth Hormone Treatment Profile (PGTP) Report for Pediatric Endocrinology","status":"COMPLETED","sponsor":"Luis Fernandez Luque","startDate":"2025-05-19","conditions":"Growth Hormone Deficiency (GHD)","enrollment":40},{"nctId":"NCT00597480","phase":"PHASE4","title":"Study of Growth-promoting and Metabolic Effects of Growth Hormone (rhGH)","status":"TERMINATED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2008-01","conditions":"Small for Gestational Age","enrollment":10},{"nctId":"NCT05602766","phase":"","title":"Ngenla Subcutaneous Injection Special Investigation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2023-02-06","conditions":"Growth Hormone Deficiency Without Epiphyseal Closure","enrollment":1},{"nctId":"NCT03972345","phase":"","title":"Influence of Adherence to Growth Hormone Therapy (GHT) With Norditropin® on Near Final Height in Patients With Growth Hormone Deficiency (GHD) and Born Small for Gestational Age (SGA)","status":"ENROLLING_BY_INVITATION","sponsor":"Novo Nordisk A/S","startDate":"2019-06-21","conditions":"Growth Hormone Deficiency in Children, Born Small for Gestational Age","enrollment":750},{"nctId":"NCT05308927","phase":"","title":"French Registry of Children Treated With Norditropin® for Short Stature Associated With Noonan Syndrome","status":"ENROLLING_BY_INVITATION","sponsor":"Novo Nordisk A/S","startDate":"2022-03-16","conditions":"Noonan Syndrome","enrollment":221},{"nctId":"NCT06109935","phase":"","title":"Special Use-results Surveillance on Long Term Use of Sogroya® in Children With Short Stature Due to Growth Hormone Deficiency Where Epiphysial Discs Are Not Closed","status":"ENROLLING_BY_INVITATION","sponsor":"Novo Nordisk A/S","startDate":"2023-10-04","conditions":"Growth Hormone Deficiency in Children","enrollment":200},{"nctId":"NCT07016802","phase":"PHASE1","title":"A Clinical Study of GenSci134 in Healthy Male Adults","status":"RECRUITING","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","startDate":"2025-06-23","conditions":"Healthy Volunteers","enrollment":64},{"nctId":"NCT05230550","phase":"","title":"Post-Marketing Surveillance (Special Use-results Surveillance on Long-term Use) With Sogroya®","status":"ENROLLING_BY_INVITATION","sponsor":"Novo Nordisk A/S","startDate":"2022-02-03","conditions":"Adult Growth Hormone Deficiency","enrollment":200},{"nctId":"NCT04614337","phase":"PHASE2","title":"Phase 2 Study of LUM-201 in Children With Growth Hormone Deficiency (OraGrowtH210 Trial)","status":"COMPLETED","sponsor":"Lumos Pharma","startDate":"2020-12-31","conditions":"Growth Hormone Deficiency","enrollment":82},{"nctId":"NCT04786873","phase":"PHASE3","title":"A Research Study of How Well Macimorelin Works to Find Out if Children Have a Lack of Growth Hormone and How Safe it is","status":"COMPLETED","sponsor":"AEterna Zentaris","startDate":"2021-11-16","conditions":"Growth Hormone Deficiency","enrollment":101},{"nctId":"NCT00537914","phase":"PHASE4","title":"Safety and Efficacy of Omnitrope® (rhGH) in Short Children Born Small for Gestational Age (SGA)","status":"COMPLETED","sponsor":"Sandoz","startDate":"2008-02-06","conditions":"Small for Gestational Age","enrollment":278},{"nctId":"NCT01562834","phase":"PHASE4","title":"Effect of Somatropin on Left Ventricular Mass in Growth Hormone Deficient Adult Patients","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"1998-10-21","conditions":"Growth Hormone Disorder, Adult Growth Hormone Deficiency","enrollment":22},{"nctId":"NCT04513171","phase":"PHASE2, PHASE3","title":"Safety and Efficacy of Y-shape Pegylated Somatropin in Growth Hormone Deficiency Children","status":"COMPLETED","sponsor":"Xiamen Amoytop Biotech Co., Ltd.","startDate":"2018-12-26","conditions":"Growth Hormone Deficiency","enrollment":434},{"nctId":"NCT01306357","phase":"","title":"Evaluation of Overall Compliance and Duration of Zomacton® Treatment With the Zomajet® Needle-free Device","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2007-09","conditions":"Turner's Syndrome, Human Growth Hormone Deficiency","enrollment":87},{"nctId":"NCT00705172","phase":"","title":"Retrospective Observational Study on Efficacy and Safety of Norditropin® in Children With Prader-Willi Syndrome","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2008-11","conditions":"Genetic Disorder, Prader-Willi Syndrome","enrollment":41},{"nctId":"NCT03223025","phase":"PHASE3","title":"Comparing Efficacy and Safety of CinnaGen Biosimilar Growth Hormone (CinnaTropin®) Versus Nordilet in Children With Idiopathic Growth Hormone Deficiency","status":"COMPLETED","sponsor":"Cinnagen","startDate":"2016-03-09","conditions":"Idiopathic Growth Hormone Deficiency","enrollment":30},{"nctId":"NCT01529944","phase":"PHASE3","title":"Genetic Testing of Noonan Subjects Previously Treated With Norditropin®. An Extension to Trial GHNOO-1658","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2008-09","conditions":"Genetic Disorder, Noonan Syndrome","enrollment":22},{"nctId":"NCT04798690","phase":"","title":"Long-term Safety and Effectiveness of Growtropin®-II Treatment in Children With Short Stature","status":"RECRUITING","sponsor":"Dong-A ST Co., Ltd.","startDate":"2021-02-08","conditions":"Growth Hormone Deficiency, Idiopathic Short Stature, Turner Syndrome","enrollment":2500},{"nctId":"NCT00572156","phase":"PHASE2","title":"rhGH and rhIGF-1 Combination Therapy in Children With Short Stature Associated With IGF-1 Deficiency","status":"TERMINATED","sponsor":"Ipsen","startDate":"2007-12","conditions":"Insulin-like Growth Factor-1 Deficiency","enrollment":106},{"nctId":"NCT04121780","phase":"PHASE2","title":"Growth Hormone Replacement Therapy for Retried Professional Football Players","status":"RECRUITING","sponsor":"Center for Neurological Studies","startDate":"2019-10-08","conditions":"TBI (Traumatic Brain Injury), Concussion, Brain, Sport Injury","enrollment":42},{"nctId":"NCT03435627","phase":"","title":"Post Marketing Surveillance on Long-term Use With Norditropin® (Short Stature Due to Noonan Syndrome)","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2018-02-26","conditions":"Genetic Disorder, Noonan Syndrome","enrollment":71},{"nctId":"NCT05089344","phase":"NA","title":"Growth Hormone Pretreatment in Poseidon Type IV Undergoing ICSI Using Minimal Induction Protocol: A Randomized Controlled Trial","status":"UNKNOWN","sponsor":"Ain Shams Maternity Hospital","startDate":"2021-10-09","conditions":"Poor Response to Ovulation Induction Poseidon Type IV","enrollment":132},{"nctId":"NCT01298180","phase":"PHASE4","title":"Is There a Sensibility Increased in the Growth Hormone at Child With Prader-Willi Syndrome?","status":"COMPLETED","sponsor":"University Hospital, Toulouse","startDate":"2009-01","conditions":"Prader-Willi Syndrome, Growth Hormone Deficiency","enrollment":111},{"nctId":"NCT03874013","phase":"PHASE3","title":"Safety and Efficacy Study of MOD-4023 to Treat Children With Growth Hormone Deficiency","status":"COMPLETED","sponsor":"OPKO Health, Inc.","startDate":"2017-12-07","conditions":"Growth Hormone Deficiency","enrollment":44},{"nctId":"NCT01626833","phase":"PHASE2, PHASE3","title":"Severe Decrease of Growth Velocity in Children With Anorexia Nervosa.Therapeutic Trial of Growth Hormone","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2013-03","conditions":"Anorexia Nervosa, Interruption of Growth, Delayed Puberty","enrollment":15},{"nctId":"NCT01263457","phase":"","title":"To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in the UK","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2010-11-30","conditions":"Growth Disorders","enrollment":191},{"nctId":"NCT01706783","phase":"PHASE1","title":"A Trial Investigating the Safety, Tolerability, Availability and Distribution in the Body of Once-weekly Long-acting Growth Hormone (Somapacitan) Compared to Once Daily Norditropin NordiFlex® in Adults With Growth Hormone Deficiency","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2012-10-12","conditions":"Growth Hormone Disorder, Adult Growth Hormone Deficiency","enrollment":35},{"nctId":"NCT01973244","phase":"PHASE1","title":"A Trial Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Dose of Long-acting Growth Hormone (Somapacitan) Compared to Daily Dosing of Norditropin® SimpleXx® in Children With Growth Hormone Deficiency","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2013-12-16","conditions":"Growth Hormone Disorder, Growth Hormone Deficiency in Children","enrollment":32},{"nctId":"NCT00488124","phase":"PHASE2","title":"Growth Response in Short Children Suffering From a Disease With Growth Retardation and Treated With Somatropin","status":"COMPLETED","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2005-11","conditions":"Idiopathic Short Stature","enrollment":120},{"nctId":"NCT03075644","phase":"PHASE3","title":"A Trial to Evaluate the Safety of Once Weekly Dosing of Somapacitan (NNC0195-0092) and Daily Norditropin® FlexPro® for 52 Weeks in Previously Human Growth Hormone Treated Japanese Adults With Growth Hormone Deficiency","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2017-03-03","conditions":"Growth Hormone Disorder, Adult Growth Hormone Deficiency","enrollment":62},{"nctId":"NCT02229851","phase":"PHASE3","title":"Trial to Compare the Efficacy and Safety of NNC0195-0092 (Somapacitan) With Placebo and Norditropin® FlexPro® (Somatropin) in Adults With Growth Hormone Deficiency.","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2014-10-31","conditions":"Growth Hormone Disorder, Adult Growth Hormone Deficiency","enrollment":301},{"nctId":"NCT00447499","phase":"PHASE3","title":"Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel","status":"COMPLETED","sponsor":"Ipsen","startDate":"2007-04","conditions":"Acromegaly","enrollment":59},{"nctId":"NCT00747604","phase":"","title":"IGFD Registry: A Patient Registry for Monitoring Long-term Safety and Efficacy of Increlex","status":"TERMINATED","sponsor":"Ipsen","startDate":"2006-06","conditions":"Primary Insulin-like Growth Factor-1 Deficiency","enrollment":1378},{"nctId":"NCT02382939","phase":"PHASE3","title":"A Trial to Compare the Safety of Once Weekly Dosing of Somapacitan With Daily Norditropin® FlexPro® for 26 Weeks in Previously Human Growth Hormone Treated Adults With Growth Hormone Deficiency","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2015-02-12","conditions":"Adult Growth Hormone Deficiency, Growth Hormone Disorder","enrollment":92},{"nctId":"NCT02015273","phase":"","title":"To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ (ECOS Taiwan, Indonesia, Singapore)","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2014-02-28","conditions":"Growth Disorders","enrollment":82},{"nctId":"NCT01947894","phase":"","title":"A Prospective Non-Interventional Study Protocol With Primary Data Collection - Assessment Of The Long Term Treatment Outcomes Of Genotropin Treatment In Growth Hormone Deficiency (GHD) Patients","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-11-20","conditions":"Growth Hormone Deficiency","enrollment":377},{"nctId":"NCT02770157","phase":"PHASE3","title":"Efficacy and Safety of DA-3002 in Short Children Borns SGA.","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2016-02-26","conditions":"Infant, Small for Gestational Age","enrollment":75},{"nctId":"NCT00216398","phase":"PHASE4","title":"Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR","status":"COMPLETED","sponsor":"Ipsen","startDate":"2004-06","conditions":"Acromegaly","enrollment":8},{"nctId":"NCT02204163","phase":"PHASE3","title":"Study to Assess the Efficacy and Safety of Eutropin in Prader-Willi Syndrome","status":"COMPLETED","sponsor":"LG Life Sciences","startDate":"2014-06","conditions":"Prader-Willi Syndrome","enrollment":34},{"nctId":"NCT01111019","phase":"PHASE2","title":"Efficacy and Safety Evaluation of Recombinant Human Growth Hormone (r-hGH), Saizen®, on a Population of Children With Hypochondroplasia, Treated at Least 3 Years or Until Near Final Height, When Applicable, in Comparison With a Historic Cohort of Non-treated Children","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2006-03-21","conditions":"Hypochondroplasia","enrollment":19},{"nctId":"NCT03800810","phase":"EARLY_PHASE1","title":"Implantation of Allogenic Mesenchymal Stem Cell From Umbilical Cord Blood for Osteoarthritis Management","status":"UNKNOWN","sponsor":"Indonesia University","startDate":"2015-05","conditions":"Osteoarthritis, Knee","enrollment":9},{"nctId":"NCT00455884","phase":"","title":"A Post Marketing Surveillance Study for NutropinAq® in Adults With Growth Hormone Deficiency","status":"COMPLETED","sponsor":"Ipsen","startDate":"2006-06","conditions":"Growth Hormone Disorders","enrollment":546},{"nctId":"NCT01110928","phase":"","title":"Observational Study of the Safety and Efficacy of Norditropin® in Patients With SGA (Small for Gestational Age) Short Stature That Are Still Growing","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2009-11-26","conditions":"Foetal Growth Problem, Small for Gestational Age","enrollment":227},{"nctId":"NCT02311894","phase":"PHASE4","title":"A Post-Marketing Study of the Immunogenicity of Somatropin (Ribosomal Deoxyribo Nucleic Acid [rDNA] Origin) Injection (Nutropin AQ®) in Children With Growth Hormone Deficiency","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2015-03-31","conditions":"Growth Hormone Deficiency","enrollment":82},{"nctId":"NCT00455728","phase":"","title":"A Post Marketing Surveillance Program for NutropinAq® in Paediatric Growth Disorders","status":"COMPLETED","sponsor":"Ipsen","startDate":"2006-06","conditions":"Growth Hormone Disorders","enrollment":3690},{"nctId":"NCT01066052","phase":"PHASE4","title":"Growth Hormone Treatment for the Prevention of Short Stature in Young Girls With Turner Syndrome Before the Age of 4 Years","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"1992-02-29","conditions":"Turner's Syndrome","enrollment":115},{"nctId":"NCT03274973","phase":"","title":"Study to Assess Long-term Effectiveness of Zomacton® and Treatment Adherence in Patients With Growth Hormone Deficiency or Ullrich-Turner Syndrome","status":"TERMINATED","sponsor":"Ferring Pharmaceuticals","startDate":"2018-05-14","conditions":"Growth Disorders","enrollment":4},{"nctId":"NCT00748969","phase":"PHASE2, PHASE3","title":"Clinical Trial of Growth Hormone in MPS I, II, and VI","status":"TERMINATED","sponsor":"Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center","startDate":"2008-11","conditions":"Mucopolysaccharidosis I, Mucopolysaccharidosis II, Mucopolysaccharidosis VI","enrollment":2},{"nctId":"NCT01813630","phase":"PHASE3","title":"A Clinical Study to Assess the Efficacy and Safety of DA-3002","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2013-02","conditions":"Turner's Syndrome","enrollment":58},{"nctId":"NCT00450190","phase":"PHASE3","title":"Saizen® E-Device User Trial","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2006-02-28","conditions":"Growth Disorders","enrollment":20},{"nctId":"NCT00082628","phase":"PHASE3","title":"Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients","status":"COMPLETED","sponsor":"EMD Serono","startDate":"2004-05-28","conditions":"HIV Infections, Lipodystrophy","enrollment":326},{"nctId":"NCT00256126","phase":"PHASE4","title":"Predictive Markers in Growth Hormone Deficiency (GHD) and Turner Syndrome (TS) Children Treated With SAIZEN®","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2005-05-31","conditions":"Growth Hormone Deficiency, Turner Syndrome","enrollment":318},{"nctId":"NCT01438528","phase":"","title":"Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ Electromechanical Device for Growth Hormone Treatment","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2011-12-31","conditions":"Growth Disorders","enrollment":75},{"nctId":"NCT01376921","phase":"","title":"To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Spain","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2012-09-30","conditions":"Growth Disorders","enrollment":300},{"nctId":"NCT01296425","phase":"","title":"To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Austria","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2011-07-31","conditions":"Growth Disorders","enrollment":50},{"nctId":"NCT01291394","phase":"","title":"To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in France","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2011-01-31","conditions":"Growth Disorders","enrollment":223},{"nctId":"NCT01582334","phase":"","title":"To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Argentina","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2013-03-31","conditions":"Growth Disorders","enrollment":68},{"nctId":"NCT01267526","phase":"","title":"A Canadian, Multi-centre, Observational Registry to Study Adherence and Long Term Outcomes of Therapy in Pediatric Subjects Using SAIZEN® Via Easypod™ Auto-injector for Growth Hormone Treatment","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2011-05-31","conditions":"Growth Disorders","enrollment":205},{"nctId":"NCT01555528","phase":"","title":"To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Mexico","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2012-04-30","conditions":"Growth Disorders","enrollment":193},{"nctId":"NCT02208076","phase":"","title":"To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Columbia","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2014-07-31","conditions":"Growth Disorders","enrollment":44},{"nctId":"NCT02015286","phase":"","title":"To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Middle East","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2014-03-31","conditions":"Growth Disorders","enrollment":7},{"nctId":"NCT01439061","phase":"","title":"To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Italy","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2012-03-31","conditions":"Growth Disorders","enrollment":220},{"nctId":"NCT01400997","phase":"","title":"Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Czech Republic","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2011-09-30","conditions":"Growth Disorders","enrollment":206},{"nctId":"NCT01400984","phase":"","title":"To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Slovakia","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2011-12-31","conditions":"Growth Disorders","enrollment":92},{"nctId":"NCT01402999","phase":"","title":"To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Hungary","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2012-05-31","conditions":"Growth Disorders","enrollment":83},{"nctId":"NCT01259778","phase":"","title":"To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in South Korea","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2011-02-28","conditions":"Growth Disorders","enrollment":224},{"nctId":"NCT01363674","phase":"","title":"To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Greece","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2013-04-30","conditions":"Growth Disorders","enrollment":180},{"nctId":"NCT01309555","phase":"","title":"To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Australia","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2011-04-30","conditions":"Growth Disorders","enrollment":33},{"nctId":"NCT01307059","phase":"","title":"To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Sweden","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2011-06-30","conditions":"Growth Disorders","enrollment":152},{"nctId":"NCT03290235","phase":"PHASE4","title":"Extension Study of Pegylated Somatropin to Treat Growth Retardation Caused by Endogenous Growth Hormone Deficiency in Children","status":"UNKNOWN","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","startDate":"2017-03-01","conditions":"Growth Retardation","enrollment":1500},{"nctId":"NCT01806298","phase":"PHASE4","title":"An Open-label Phase 4 Study to Explore Immunogenicity of the Liquid Formulation of Saizen® in Subjects With Adult Growth Hormone Deficiency (AGHD)","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2013-06","conditions":"Adult Growth Hormone Deficiency","enrollment":78},{"nctId":"NCT02655263","phase":"NA","title":"Substrate Metabolism, Growth Hormone Signaling (GH), and Insulin Sensitivity During GH and Ketone Bodies Infusion","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2016-01","conditions":"Healthy","enrollment":10},{"nctId":"NCT00960128","phase":"","title":"Observational Prospective Study on Patients Treated With Norditropin®","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2006-04-01","conditions":"Growth Hormone Disorder, Growth Hormone Deficiency in Children, Adult Growth Hormone Deficiency","enrollment":21249},{"nctId":"NCT00249821","phase":"PHASE3","title":"Optimization of the Dosage Regimen of Growth Hormone Therapy in Children Born Small for Gestational Age","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2005-02-28","conditions":"Small Gestational Age (SGA)","enrollment":22},{"nctId":"NCT03221088","phase":"PHASE2","title":"A Study of PEG-somatropin in the Treatment of Children With Idiopathic Short Stature","status":"UNKNOWN","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","startDate":"2015-06","conditions":"Dwarfism","enrollment":360},{"nctId":"NCT01778023","phase":"PHASE3","title":"Efficacy and Safety of Recombinant Human Growth Hormone on Height Velocity in Subjects With Idiopathic Short Stature","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2013-01-17","conditions":"Growth Disorder, Idiopathic Short Stature","enrollment":54},{"nctId":"NCT03031535","phase":"PHASE1","title":"Study of Intranasal Octreotide (DP1038) in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Dauntless Pharmaceuticals","startDate":"2017-01","conditions":"Healthy Volunteer Study","enrollment":32},{"nctId":"NCT01435629","phase":"","title":"A Survey Collecting Data on Adult Height in Patients With Achondroplasia Treated With Somatropin","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2012-11-22","conditions":"Genetic Disorder, Achondroplasia","enrollment":81},{"nctId":"NCT01009905","phase":"","title":"An Observational Study (Registry) Assessing Treatment Outcomes and Safety for Children and Adults Who Are Prescribed Norditropin® (Human Growth Hormone)","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2002-06-24","conditions":"Growth Hormone Disorder, Pituitary Dwarfism, Hypopituitarism","enrollment":22960},{"nctId":"NCT00567385","phase":"PHASE4","title":"Liquid Somatropin Formulation in Children With Growth Hormone Deficiency","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2003-03-10","conditions":"Growth Hormone Disorder, Growth Hormone Deficiency in Children","enrollment":176},{"nctId":"NCT01502124","phase":"PHASE3","title":"Safety and Efficacy of Somatropin in Children With Growth Hormone Deficiency","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2001-05-08","conditions":"Growth Hormone Disorder, Growth Hormone Deficiency in Children","enrollment":78},{"nctId":"NCT01518036","phase":"PHASE3","title":"Use of Somatropin in Turner Syndrome","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"1987-09-14","conditions":"Genetic Disorder, Turner Syndrome","enrollment":57},{"nctId":"NCT01516229","phase":"","title":"Special Survey for Long Term Application","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"1997-05-01","conditions":"Genetic Disorder, Achondroplasia","enrollment":395},{"nctId":"NCT00931476","phase":"PHASE1","title":"A Single Dose Trial in Healthy Caucasians and Japanese Subjects Investigating the Pharmacokinetics of Somatropin","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2000-04-06","conditions":"Growth Hormone Disorder, Adult Growth Hormone Deficiency, Healthy","enrollment":86},{"nctId":"NCT01245374","phase":"PHASE4","title":"Norditropin NordiFlex® Device Compared to the Device Previously Used by Patients or Parents","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2010-11","conditions":"Growth Hormone Disorder, Growth Hormone Deficiency in Children, Foetal Growth Problem","enrollment":103},{"nctId":"NCT01401244","phase":"PHASE1","title":"Bioequivalence of Two Somatropin Products (Norditropin® Versus Genotropin®) in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2011-07-14","conditions":"Genetic Disorder, Prader-Willi Syndrome, Growth Disorder","enrollment":30},{"nctId":"NCT00097539","phase":"","title":"National Cooperative Growth Study (NCGS): A Post-marketing Surveillance Program for Nutropin, Nutropin AQ, Nutropin Depot, and Protropin","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"1985-10","conditions":"Growth Disorders","enrollment":65205},{"nctId":"NCT01034202","phase":"PHASE1","title":"Dose Study in Healthy Males Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC126-0083 Compared to Norditropin® SimpleXx®","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2007-08","conditions":"Growth Hormone Disorder, Healthy","enrollment":56}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":39,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Recombinant human growth hormone (r-hGH)","mammalian cell-derived recombinant human growth hormone","r hGH","recombinant human growth hormone (r-hGH)"],"phase":"marketed","status":"active","brandName":"Serostim®","genericName":"Serostim®","companyName":"EMD Serono","companyId":"emd-serono","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Serostim is a recombinant human growth hormone that stimulates anabolic processes and increases lean body mass in patients with HIV-associated wasting. Used for HIV-associated wasting or cachexia in patients with HIV infection and low body weight.","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}